Valuation : Northwest Biotherapeutics, Inc

Market Cap 289M 249M 234M 213M 399M 27.49B 401M 2.77B 1.07B 14B 1.08B 1.06B 44.36B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 385M 331M 312M 284M 532M 36.63B 534M 3.7B 1.43B 18.66B 1.45B 1.41B 59.12B EV / Sales 2026 *
-
EV / Sales 2027 * 10.6x
Free-Float
95.22%
Yield 2026 *
-
Yield 2027 * -
08-14 Northwest Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
08-06 Northwest Biotherapeutics and Saudi Pharmaceutical Industries and Medical Appliance Company Enter Memorandum of Understanding for Collaboration CI
07-08 Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of Dcvax-L for Glioblastoma CI
05-15 Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-21 Northwest Biotherapeutics Establishes Dedicated Leukapheresis Clinic CI
04-15 Northwest Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
04-14 Northwest Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt CI
11-14 Northwest Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
11-13 Northwest Biotherapeutics, Inc. announced that it expects to receive $4.75 million in funding from Yorkville Advisors Global LP CI
31/10/25 Northwest Biotherapeutics, Inc. Enters into A Commercial Loan Agreement and Note with Streeterville Capital, LLC CI
26/10/25 Northwest Biotherapeutics, Inc. announced that it has received $5.505 million in funding CI
23/10/25 Northwest Biotherapeutics, Inc. completed the acquisition of Advent Bioservices Ltd from Toucan Holdings LLC. CI
26/08/25 Northwest Biotherapeutics, Inc. entered into an agreement to acquire Advent Bioservices Ltd from Toucan Holdings LLC for £1.4 million. CI
Manager TitleAgeSince
Chief Executive Officer 82 31/05/2007
Chief Executive Officer 71 07/06/2011
Chief Tech/Sci/R&D Officer 67 31/12/1999
Director TitleAgeSince
Director/Board Member 82 31/12/1997
Chairman 71 16/05/2007
Director/Board Member 57 31/03/2012
Change 5-day change 1-year change 3-year change Capi.($)
-0.94%+0.31%+40.04%+103.25% 69.19B
-0.07%-3.93%+32.54%+75.96% 62.97B
+3.84%+2.33%-11.97%+388.98% 27.27B
-0.16%-5.47%-3.88%-16.80% 24.78B
-0.93%-1.29%+25.30%+16.70% 25.8B
-1.43%-1.89%+21.32%-17.67% 20.11B
-4.27%+2.67%+219.02%+362.48% 18.47B
-1.43%-1.80%-8.64%+537.09% 14.88B
+0.36%-0.97%+51.42%+163.60% 14.29B
Average -0.55%-0.31%+40.57%+179.29% 30.86B
Weighted average by Cap. -0.41%-0.76%+36.47%+141.19%

Financials

2026 *2027 *
Net sales - 38.93M 33.5M 31.55M 28.74M 53.78M 3.7B 53.99M 374M 144M 1.89B 146M 143M 5.98B
Net income - -
Net Debt 96.08M 82.68M 77.85M 70.93M 133M 9.14B 133M 923M 357M 4.66B 361M 353M 14.76B 125M 108M 101M 92.24M 173M 11.89B 173M 1.2B 464M 6.06B 469M 459M 19.19B
Logo Northwest Biotherapeutics, Inc
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and includes treatment of a diverse range of more than a dozen types of cancers. Its subsidiaries include Flaskworks LLC, NW Bio GmbH, Northwest Biotherapeutics Capital Limited, Northwest Biotherapeutics B.V., Advent BioServices Ltd., and others.
Employees
-
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!